One might predict that these HER2‐amplified tumours would be resistant to cetuximab or panitumumab therapy, and that they may respond to targeted treatment against HER2, or a combination of therapies targeting HER2, EGFR and possibly also HER3. Here, ERBB3 is linked to neoplasm.